Anti-11[E]-pyroglutamate-modified amyloid - antibodies cross-react with other pathological Aβ species: Relevance for immunotherapy

Journal of Neuroimmunology

Volumn 229, Issue 1-2, 2010, Pages 248-255

  Perez Garmendia, Roxanna ^a   Ibarra Bracamontes, Vanessa ^a   Vasilevko, Vitaly ^b   Luna Muñoz, Jose ^c   Mena, Raul ^c   Govezensky, Tzipe ^a   Acero, Gonzalo ^a   Manoutcharian, Karen ^a   Cribbs, David H ^b,d   Gevorkian, Goar ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease immunotherapy; B cell epitope; Immunodominant epitope; N truncated amyloid beta (A ) peptide

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; EPITOPE; N TRUNCATED MODIFIED AMYLOID BETA PEPTIDE BEARING AMINO TERMINAL PYROGLUTAMATE 11 ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL PROTECTION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; B-LYMPHOCYTES; BRAIN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; HUMANS; NEUROBLASTOMA; PROTEIN BINDING; PYRROLIDONECARBOXYLIC ACID; RABBITS;

EID: 78649443534     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.08.020     Document Type: Article

References (43)

1. Acero G., Manoutcharian K., Vasilevko V., Munguia M.E., Govezensky T., as G., Luz-madrigal A., Cribbs D., Gevorkian G. Immunodominant epitope and properties of pyroglutamate-modified Ab-specific antibodies produced in rabbits. J Neuroimmunol 2009, 213:39-46.
2. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch K., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid-β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 2000, 6:916-919.
3. Bayer T.A., Breyahn H., Duan K., Rettig J., Wirths O. Intraneuronal β-amyloid is a major risk factor - novel evidence from the APP/PS1KI mouse model. Neurodegener Dis 2008, 5:140-142.
4. Biscaro B., Lindvall O., Hock C., Efdahl C., Nitsch R.M. Aβ immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci 2009, 29:14108-14119.
5. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008, 31:175-193.
6. Casas C., Sergeant N., Itier J.-M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a Novel Alzheimer transgenic model. Am J Pathol 2004, 165:1289-1300.
7. D'Arrigo C., Tabaton M., Perico A. N-terminal truncated pyroglutamyl β amyloid peptide Aβpy3-42 shows faster aggregation kinetics than the full-length Aβ1-42. Biopolymers 2009, 91:861-873.
8. Gevorkian G., Petrushina I., Manoutcharian K., Ghochikyan A., Acero G., Vasilevko V., Cribbs D.H., Agadjanyan M.G. Mimotopes of conformational epitopes in fibrillar β-amyloid. J Neuroimmunol 2004, 156:10-20.
9. Guntert A., Dobeli H., Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143:461-475.
10. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
11. He W., Barrow C.J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have geater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999, 38:10871-10877.
12. Head E., Pop V., Vasilevko V., Hill M., Saing T., Sarsoza F., Nistor M., Christie L.A., Milton S., Glabe C., Barrett E., Cribbs D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 2008, 28:3555-3566.
13. Huse J.T., Liu K., Pijak D.S., Carlin D., Lee V.M.-Y., Doms R.W. β-Secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J Biol Chem 2002, 277:16278-16284.
14. Klein W.L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002, 41:345-352.
15. Kumar-Singh S., De Jonghe C., Cruts M., Kleinert R., Wang R., Mercken M., De Strooper B., Vanderstichele H., Lofgren A., Vanderhoeven I., Backhovens H., Vanmechelen E., Kroisel P.M., Van Broeckhoven C. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet 2000, 9:2589-2598.
16. Lee E.B., Skovronsky D.M., Abtahian F., Doms R.W., Lee V.M.-Y. Secretion and intracellular generation of truncated Aβ in β-site amyloid-β precursor protein-cleaving enzyme expressing human neurons. J Biol Chem 2003, 278:4458-4466.
17. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res 2009, 175:83-92.
18. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., Zheng J.B., Seabrook T.J., Louard D., Li D., Selkoe D.J., Palmour R.M., Ervin F.R. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004, 165:283-297.
19. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J.Q., Lee V.M.-Y. Characterization of Aβ11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer's disease. Acta Neuropathol 2006, 112:163-174.
20. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreyther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82:4245-4249.
21. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
22. Mori H., Takio K., Ogawara M., Selkoe D.J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 1992, 267:17082-17086.
23. Naslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A.D., Tjernberg L.O., Silberring J., Gandy S.E., Winblad B., Greengard P., Nordstedt C., Terenius L. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994, 91:8378-8382.
24. Piccini A., Russo C., Gliozzi A., Relini A., Vitali A., Borghi R., Giliberto L., Armirotti A., D'Arrigo, Bachi A., Cattaneo A., Canale C., Torrassa S., Saido T.C., Markesbery W., Gambetti P., Tabaton M. β-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 2005, 280:34186-34192.
25. Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 1995, 270:23895-23898.
26. Rubinstein N.D., Mayrose I., Martz E., Pupko T. Epitopia: a web-server for predicting B-cell epitope. BMC Bioinform 2009, 10:287.
27. Russo C., Violani E., Salis S., Venezia V., Dolcini V., Damonte G., Benatti U., D'Arrigo C., Patrone E., carlo, P., Schettini G. Pyroglutamate-modified amyloid-peptides - A N3(pE) - strongly affect cultured neuron and astrocyte survival. J Neurochem 2002, 82:1480-1489.
28. Saha S., Raghava G.P.S. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 2006, 65:40-48.
29. Saido T.C., Iwatsubo T., Mann D.M.A., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 1995, 14:457-466.
30. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
31. Schilling S., Lauber T., Schaupp M., Manhart S., Scheel E., Bohm G., Demuth H.-U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45:12393-12399.
32. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Sch lenzig D., Landler C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nat Med 2008, 14:1106-1111.
33. Sergeant N., Bombois S., Ghestem A., Drobecq H., Kostanjevecki V., Missiaen C., Wattez A., David J.-P., Vanmechelen E., Sergheraert C., Delacourte A. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003, 85:1581-1591.
34. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schiossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., Schenk D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
35. Solrzano-Vargas R.S., Vasilevko V., Acero G., Ugen K.E., Martinez R., Govezensky T., Vazquez-Ramirez R., Kubli-Garfias C., Cribbs D.H., Manoutcharian K., Gevorkian G. Epitope mapping and neuroprotective properties of a human single Chain Fv antibody that binds an internal epitope of amyloid-beta 1-42. Mol Immunol 2008, 45:881-886.
36. Tekirian T.L., T.C., Markesbery W.R., Russel M.J., Wekstein D.R., Patel E., Geddes J.W. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol 1998, 57:76-94.
37. Vanderstichele H., De Meyer G., Andreasen N., Kostanjevecki V., Wallin A., Olsson A., Blennow K., Vanmechelen E. Amino-truncated β-amyloid 42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005, 51:1650-1660.
38. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secterase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
39. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
40. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M.J., Gordon M.N., Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004, 24:6144-6151.
41. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.-U., bayer T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009, 118:487-496.
42. Wirths O., Bethge T., Marcello A., Harmeier A., Jawhar S., Lucassen P.J., Milthaup G. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010, 117:85-96.
43. Youssef I., Florent-Bechard S., malaplate-Armand C., Koziel V., Bihain B., Olivier J.-L., Leininger-Muller B., Kriem B., Oster T., Pillot T. N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 2007, 29:1319-1333.